CFI-402411 not checked
Treadwell Therapeutics, Inc · 2411 · 402411
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.”In the company’s words, NCT04521413 on ClinicalTrials.gov
- Tested for
- Advanced Solid Malignancies
- Main trialPhase 1/2
- “The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.”In the company’s words, NCT04521413 on ClinicalTrials.gov
- Other names
- 2411 · 402411
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Unknown | Nov 2025 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026